Sanofi Aventis is facing a new Taxotere lawsuit from a South Carolina woman and her husband, alleging permanent hair loss from chemo after using the drug for treatment.

Plaintiff Linda and Larry G. allege that the company failed to warn them against permanent hair loss from chemo, and that Linda never would have used Taxotere if she had known the risk.

According to the Taxotere lawsuit, Linda was diagnosed with breast cancer in June 2013 and was forced to contend with the condition and the rigorous treatment process.

On August 2013, Linda had began Taxotere treatment and continued chemotherapy treatments though November 2013.

While Linda had lost her hair during chemotherapy, a common side effect of the process, she did not expect to develop permanent hair loss from chemo.

This has caused her to suffer even more pain ad suffering, with her husband alleging it severely impacted their marriage.

Permanent Hair Loss From Chemo

Taxotere was approved by the FDA in the early 1990s, to be a chemotherapy treatment drug for breast cancer.

Taxotere has been approved to treat a number of other cancers since its release, treating millions of patients suffering from cancer.

Even though Taxotere has been praised for its effective treatment mechanism, numerous women have reported permanent hair loss from chemo.

Similar to other chemotherapy drugs, Taxotere works by attacking rapidly reproducing cells and is designed to kill the cancer cells before they spread.

However many patients experience hair loss in result, as hair follicles are some of the body’s fastest reproducing cells.

Patients can typically expect their hair to grow back as time passes after chemotherapy, but Taxotere patients have reported differently.

During her time taking Taxotere and reviewing different treatment options, Linda and her oncologist were allegedly unaware of the risk of permanent hair loss from chemo.

Sanofi Aventis had allegedly failed to provide any kind of relevant studies, and failed to mention the possibility of permanent hair loss from chemo on Taxotere’s warning label.

The risk of Taxotere permanent hair loss from chemo was not mentioned until December 2015, when the FDA required a label update.

The agency ordered this change after receiving numerous complaints of alopecia.

Sanofi Aventis allegedly knew the risk of Taxotere and permanent hair loss from chemo for years, but concealed the information for years to protect the drug’s market value.

Linda states that she never would have taken Taxotere if she had known the risk of permanent hair loss from chemo.

She and her husband are filing legal action against Sanofi Aventis for failure to warn and multiple counts of negligence.

The Taxotere Hair Loss Lawsuit is Case No.1:16-cv-6883, in the U.S. District Court for the Southern District of New York.